Leon Recanati - Evogene Independent Director

EVGN Stock  ILA 241.10  18.60  7.16%   

Director

Mr. Leon Yehuda Recanati serves as Independent Director at Evogene Ltd since May 2005. He is a member of the Corporationrationrate Development committee. His work experience includes the following roles chairman and chief executive officer of GlenRock Israel Ltd, Chief Executive Officer andor Chairman of IDB Holding Corporationrationration, Clal Industries Ltd, Azorim Investment Development and Construction Co Ltd, Delek Israel Fuel Corporation and SuperSol Ltd, Founder of Clal Biotechnologies Industries Ltd, Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association and Chairman of TelAviv University Development Committee, active Member of the Board of Governors of TelAviv University and The Hebrew University of Jerusalem, The Technion Israel Institute of Technology, The Jewish Agency and Chairman of Tapuah The Israeli Society for the Advancement of the Information Age. He holds a Bachelors degree in Economics and a MBA degree, both from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and TelAviv University. since 2005.
Age 71
Tenure 19 years
Professional MarksMBA
Phone(972) 8 946 6724
Webwww.evogene.com
Recanati received his BA in Economics and MBA degree, both from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and TelAviv University.

Evogene Management Efficiency

The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.39 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Evogene has a current ratio of 12.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Evogene until it has trouble settling it off, either with new capital or with free cash flow. So, Evogene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evogene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evogene to invest in growth at high rates of return. When we think about Evogene's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

DIRECTOR Age

Eran PerryCompugen
N/A
Yair AharonowitzCompugen
73
Sanford ZweifachCompugen
60
JeanPierre BizzariCompugen
64
Ruth ArnonCompugen
86
Kinneret SavitskyCompugen
50
Dov HershbergCompugen
74
Joshua ShemerCompugen
63
Gilead HalevyCompugen
51
Arie OvadiaCompugen
67
Michal PremingerCompugen
N/A
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people. Evogene (EVGN) is traded on Tel Aviv Stock Exchange in Israel and employs 133 people.

Management Performance

Evogene Leadership Team

Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Kapel, Executive Vice President-Technology
Assaf Oron, Executive VP Corporate Devel.
Martin Gerstel, Chairman of the Board
Oded Shoseyov, Director
Eyal Leibovitz, CFO
Yaron Eldad, Chief Officer
Eyal Ronen, Exec Devel
Adina Makover, Independent Director
Adrian Percy, Director
Sarit Firon, Independent Director
Sassi Masliah, Exec Devel
Yuval BenGalim, COO
Michael Anghel, External Director
Liat Wejgman, VP HR
Eran Kosover, Executive Vice President & General Manager Ag-Chemicals
Ofer CPA, CEO Pres
Ofer Haviv, President, Chief Executive Officer
Amos Shachar, Vice President of Project Management
Ido Dor, Executive Vice President & General Manager Ag-Biologicals
Sigal Fattal, Executive Officer
Dotan Borenstein, Chief Ltd
Nir Arbel, Chief Officer
Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals
Leon Recanati, Independent Director
Alin SelaBrown, Vice President Screening & Validation Systems
Kinneret Savitsky, Independent Director
Eli Zangvil, Director
Eyal Emmanuel, Executive Vice President-R&D
Assaf Kacen, Chief Operation Officer
Arnon Heyman, Vice President & General Manager of Ag-Seeds
Kinneret Savitzky, External Director
Simcha Sadan, Director
Alex Taskar, Chief Financial Officer
Lea Bloom, Director of Administration & Human Resources
Ziv Kop, Independent Director
Elran MBA, Chief Ltd

Evogene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evogene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evogene's short interest history, or implied volatility extrapolated from Evogene options trading.

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving against Evogene Stock

  0.61PRTC PriortechPairCorr
  0.48PSTI PluristemPairCorr
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Evogene Stock analysis

When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.